Astrana Health, Inc. (ASTH) Guidance & Earnings Results
On 2026-08-06 Astrana Health, Inc. raised guidance: "FY2026 adjusted EBITDA guidance raised to $255-280M (from prior); revenue reaffirmed $3.8-4.1B; FCF reaffirmed…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ASTHAstrana Health, Inc.Follow ASTH — free
—
Price chart with a free account
- Market cap
- 2.1B
- P/E TTM
- 45.1
- Dividend yield
- 0.0%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 6 Aug 26 | Raised | FY2026 adjusted EBITDA guidance raised to $255-280M (from prior); revenue reaffirmed $3.8-4.1B; FCF reaffirmed $105-132.5M · full year |
| 6 Nov 25 | Reaffirmed | Full-year 2025 revenue $3.1-3.18B, adjusted EBITDA $200-210M · full year |
| 7 Aug 25 | Reaffirmed | FY2025 total revenue $3.1B-$3.3B; FY2025 adjusted EBITDA $215M-$225M; Q3 2025 total revenue $925M-$965M; Q3 2025 adjusted EBITDA $65M-$70M · full year |
Astrana Health, Inc. — questions
- What guidance did Astrana Health, Inc. give?
- On 2026-08-06: "FY2026 adjusted EBITDA guidance raised to $255-280M (from prior); revenue reaffirmed $3.8-4.1B; FCF reaffirmed $105-132.5M"
- When does Astrana Health, Inc. report earnings?
- Astrana Health, Inc.'s next earnings report is expected on 2026-11-05.
Every figure on this page comes from Astrana Health, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.